Abstract: This invention relates to a flavonoid composition that includes eriocitrin. The flavonoid may be included in a complex with other bioflavonoids. The composition may also include neoeriocitrin. This invention also relates to methods of using the composition, including for reducing IL-6 or MCP-1 treating inflammation, and treating symptoms of metabolic syndrome.

Abstract: This invention relates to a flavonoid composition that includes eriocitrin. The flavonoid may be included in a complex with other bioflavonoids. The composition may also include neoeriocitrin. This invention also relates to methods of using the composition, including for reducing IL-6 or MCP-1 treating inflammation, and treating symptoms of metabolic syndrome.

Abstract: This invention relates to a flavonoid composition that includes eriocitrin. The flavonoid may be included in a complex with other bioflavonoids. The composition may also include neoeriocitrin. This invention also relates to methods of using the composition, including for reducing IL-6 or MCP-1 levels, treating inflammation, and treating symptoms of metabolic syndrome.

Abstract: This invention relates to a flavonoid composition that includes eriocitrin. The flavonoid may be included in a complex with other bioflavonoids. The composition may also include neoeriocitrin. This invention also relates to methods of using the composition, including for reducing IL-6 or MCP-1 levels, treating inflammation, and treating symptoms of metabolic syndrome.

Abstract: A method for removing furanocoumarins from a liquid includes the steps of incubating the liquid with fungal hyphae for at least about two hours and removing the hyphae from the liquid by a filtration step. The furanocoumarins can be recovered from the hyphae using methods within the ordinary skill in the art. The method is useful for the removal of furanocoumarins from furanocoumarin-containing citrus juice so that the juice can be safely consumed by humans taking drugs that are metabolized by P450 CYP3A, which is the enzyme responsible for the metabolism of many widely-prescribed medications.

Abstract: Embodiments of the invention are directed to manufacturing a medical device in a way that minimizes the possibility of defects. Because of the general increasing desire to eliminate lead from the environment, electronic producers are removing lead from their manufacturing processes. The lead had beneficial qualities, however, in that it prevented other metals, in particular tin, from developing “whiskers,” believed to be caused from thermal and mechanical stress of the tin parts or components. Removing the lead has caused an increasing incidence of failure in electronic devices. Many vendors, believing that lead-free devices are universally desirable, routinely substitute lead-free components for components that previously contained lead. Oftentimes these substitutions are made without knowledge of the buyer. Some devices, in particular life-saving devices, may be adversely affected by such a substitution.

Abstract: Compositions and methods for the treatment, reduction and/or prevention of cardiovascular diseases and disorders are described. Individuals at high risk for developing or having cardiovascular disease or disorder may be treated with an effective dose of a polymethoxyflavone including limocitrin derivatives, quercetin derivatives, naturally occurring polymethoxyflavones, tocotrienols, and mixtures of these compounds.

Abstract: Compositions and methods for the treatment, reduction and/or prevention of cardiovascular diseases and disorders are described. Individuals at high risk for developing or having cardiovascular disease or disorder may be treated with an effective dose of a polymethoxyflavone including limocitrin derivatives, quercetin derivatives, naturally occurring polymethoxyflavones, tocotrienols, and mixtures of these compounds.

Abstract: Compositions and methods for the treatment, reduction and/or prevention of cardiovascular diseases and disorders are described. Individuals at high risk for developing or having cardiovascular disease or disorder may be treated with an effective dose of a polymethoxyflavone including limocitrin derivatives, quercetin derivatives, naturally occurring polymethoxyflavones, tocotrienols, and mixtures of these compounds.

Abstract: A method of inhibiting the production of cytokines, particularly inhibiting the production of tumor necrosis factor&agr;, interleukin-10, and macrophage inflammatory protein-1&agr; and the like, in a mammal, including a human, in need thereof which involves administering to such mammal an effective amount, preferably cytokine production inhibiting amount, of a polymethoxylated flavone.

Abstract: An improved hammer bank assembly includes a plurality of spaced-apart hammers, each of the hammers including a substantially planar hammer body containing an electrical coil, with each hammer body being supported for movement in a predetermined plane. A hammer head is attached to and coplanar with each hammer body. Also included are a plurality of flat permanent magnets interleaved with the plurality of hammers so that adjacent ones of the permanent magnets oppose but are separated from each hammer body. A plurality of hammer guide members are provided, one for each hammer, with each hammer guide member defining therein an elongated groove in which is received at least a portion of each hammer head.